STOCK TITAN
  1. Home
  2. Sec-filings
  3. AUTL
  4. [Form 4] Autolus Therapeutics plc Insider Trading Activity

Autolus Therapeutics (AUTL) director receives new option and RSU equity awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Autolus Therapeutics plc director Robert Iannone received new equity awards. He was granted options covering 47,500 American Depositary Shares at an exercise price of $1.6100 per share, vesting in twelve equal monthly installments starting on July 29, 2026, and expiring on June 29, 2036.

He also received 31,667 restricted share units, each representing one American Depositary Share, which will vest in a single installment on June 29, 2027. Each American Depositary Share is convertible into one ordinary share of Autolus Therapeutics.

Positive

  • None.

Negative

  • None.
Insider Iannone Robert
Role null
Type Security Shares Price Value
Grant/Award Restricted Share Units 31,667 $0.00 --
Grant/Award Share Option (Right to Buy) 47,500 $0.00 --
Holdings After Transaction: Restricted Share Units — 31,667 shares (Direct, null); Share Option (Right to Buy) — 47,500 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. The RSUs vest in one installment on June 29, 2027. Share options vest in twelve equal monthly installments commencing on July 29, 2026.
Option grant size 47,500 shares Share options on American Depositary Shares granted to director
Option exercise price $1.6100 per share Exercise price for granted share options
Option expiration June 29, 2036 Expiration date of share options
RSU grant size 31,667 units Restricted share units linked to American Depositary Shares
RSU vesting date June 29, 2027 Single installment vesting date for RSUs
Restricted Share Units financial
"security_title": "Restricted Share Units""
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
American Depositary Shares financial
"underlying_security_title": "American Depositary Shares""
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
Share Option (Right to Buy) financial
"security_title": "Share Option (Right to Buy)""
vest in twelve equal monthly installments financial
"Share options vest in twelve equal monthly installments commencing on July 29, 2026."
contingent right to receive financial
"Each restricted stock unit (RSU) represents a contingent right to receive one share"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Iannone Robert
(Last)(First)(Middle)
THE MEDIAWORKS, WHITE CITY
C/O AUTOLUS THERAPEUTICS PLC
(Street)
LONDONW12 7FP
(City)(State)(Zip)
UNITED KINGDOM
(Country)		2. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Share Units(1)06/29/2026A31,667 (2) (2)American Depositary Shares31,667$031,667D
Share Option (Right to Buy)$1.6106/29/2026A47,500 (3)06/29/2036American Depositary Shares47,500$047,500D
Explanation of Responses:
1. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's American Depositary Shares. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
2. The RSUs vest in one installment on June 29, 2027.
3. Share options vest in twelve equal monthly installments commencing on July 29, 2026.
/s/ Robert Iannone07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Autolus Therapeutics (AUTL) report for Robert Iannone?

Autolus Therapeutics reported that director Robert Iannone received equity awards, not open‑market trades. He was granted 47,500 share options and 31,667 restricted share units, both linked to the company’s American Depositary Shares as part of his compensation.

How many options did Robert Iannone receive in the latest AUTL Form 4?

Robert Iannone received a grant of 47,500 share options in Autolus Therapeutics. These options relate to American Depositary Shares and carry an exercise price of $1.6100 per share, with vesting spread over twelve equal monthly installments beginning in July 2026.

What are the key terms of Robert Iannone’s option grant at Autolus Therapeutics (AUTL)?

The option grant covers 47,500 American Depositary Shares at an exercise price of $1.6100 per share. These share options vest in twelve equal monthly installments starting on July 29, 2026, and they are scheduled to expire on June 29, 2036.

What restricted share units did Robert Iannone receive from Autolus Therapeutics (AUTL)?

Robert Iannone received 31,667 restricted share units tied to American Depositary Shares. Each RSU represents a contingent right to receive one ADS, and these RSUs will vest in a single installment on June 29, 2027, subject to the standard conditions.

How do Autolus Therapeutics (AUTL) RSUs and ADSs relate to ordinary shares?

Each restricted share unit represents a right to receive one American Depositary Share. According to the disclosure, each American Depositary Share is convertible into one ordinary share of Autolus Therapeutics at the option of the reporting person, linking RSUs directly to ordinary equity.

Were Robert Iannone’s Autolus Therapeutics (AUTL) transactions open-market buys or sells?

The transactions for Robert Iannone were grants of equity awards, not open‑market buying or selling. Both entries are coded as grants/awards, reflecting compensation-related acquisitions of options and restricted share units rather than discretionary trades in the market.